Full-Time
Posted on 9/30/2025
Global medical devices and diagnostics provider
$114.5k - $189.1k/yr
Midland Park, NJ, USA
Hybrid
| , , |
BD is a global medical technology company serving hospitals, labs, and healthcare providers with products across BD Medical, Life Sciences, and Interventional. Its offerings include medication management and delivery devices, safe specimen collection and transport systems, and minimally invasive surgical instruments. Its products help safe medication administration, preserve specimen integrity for diagnostics, and enable less-invasive procedures, saving time and improving outcomes. BD differentiates itself with a broad end-to-end portfolio, global reach, and focus on quality, safety, and service to support care across regions; its goal is to improve patient outcomes, lower costs, and increase efficiency in care environments.
Company Size
10,001+
Company Stage
IPO
Headquarters
Franklin Lakes, New Jersey
Founded
1961
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Tuition Reimbursement
Becton Dickinson reported second-quarter fiscal 2025 results with revenue growing 6%, or 0.9% organically, falling below expectations. The medical device company cited market challenges in its Life Sciences segment, including changes in research funding policy and slower-than-expected recovery in blood culture testing within Diagnostics. Chairman and CEO Tom Polen acknowledged dissatisfaction with the top-line performance, noting it doesn't reflect the mid-single-digit growth BD has consistently delivered in recent years. The company is implementing strategic actions and investments to reaccelerate organic sales growth. Despite revenue challenges, BD exceeded adjusted earnings per share expectations, delivering adjusted gross margins of 54.9%, up 190 basis points year-over-year. This marks the fourth consecutive quarter of strong gross margin expansion driven by the company's BD Excellence initiative.
Rick Byrd to retire from BD. Apr 09, 2026, 16:05 ET FRANKLIN LAKES, N.J., April 9, 2026 /PRNewswire/ - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Richard (Rick) Byrd has informed the company of his intent to retire after nearly 25 years with BD. Byrd is currently executive vice president and president of the Interventional Segment at BD, a position he has held since September 2022. During his tenure, Byrd held several leadership roles including worldwide president of Medication Delivery Solutions and worldwide president of Preanalytical Systems. Prior to joining BD in 2004, Byrd held various leadership and engineering positions across the medical device and advanced technology sectors. "Over his long career, Rick has led his teams to deliver meaningful results for BD - strengthening our portfolio, elevating our operational rigor and advancing BD's role as a global healthcare leader," said Tom Polen, chairman, CEO and president of BD. "Rick has driven impact across multiple segments, including expanding BD's leadership in Vascular Access Management, advancing our 'One-Stick Hospital Stay' vision and leading critical manufacturing scale-up efforts during the COVID-19 pandemic. We thank Rick for his many contributions to BD and wish him all the best in his retirement." Byrd will remain in his role through June. BD intends to name a successor prior to Byrd's retirement date. "What has inspired me most throughout my time at BD is the people - the teams who show up every day committed to driving the future of care and improving outcomes for patients everywhere," Byrd said. "I'm incredibly proud of the meaningful work we've accomplished together and am confident that BD will continue to deliver on its purpose of advancing the world of health." About BD BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health(TM) by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson. | Contacts: | / | | Media | Investors | | Megan Dubrowski Senior Director, Executive Communications [email protected] | Shawn Bevec SVP, Investor Relations [email protected] | SOURCE BD (Becton, Dickinson and Company)
BD has received CE Mark approval for its Liverty TIPS Stent Graft, bringing next-generation portal hypertension treatment to the European Union. The device features an adjustable 6–10mm inner diameter and offers the broadest range of covered stent lengths currently available for transjugular intrahepatic portosystemic shunt procedures. Designed for patients with cirrhosis complications, the device uses a flexible nitinol frame and dual-layer ePTFE encapsulation delivered via a triaxial system. An estimated 58 million people worldwide live with cirrhosis, which can lead to life-threatening portal hypertension complications. Safety and effectiveness data from the pivotal ARCH clinical trial will be presented at the Society of Interventional Radiology Annual Scientific Meeting on 12 April 2026. The device remains investigational in the United States.
BD delivers next-generation TIPS innovation to advance portal hypertension care across the European Union. CE Marking and ARCH clinical trial data position the Liverty(TM) TIPS Stent Graft to expand treatment options for patients with advanced liver disease FRANKLIN LAKES, N.J., April 8, 2026 /PRNewswire/ - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced application of CE Mark for the Liverty(TM) TIPS Stent Graft, delivering innovation to portal hypertension care across the European Union. Designed to expand treatment options for patients with cirrhosis and complications of portal hypertension, our next-generation, adjustable-diameter device represents the latest advancement by BD in interventional therapies addressing complex liver disease. Safety and effectiveness data from the pivotal ARCH clinical trial evaluating the Liverty(TM) TIPS Stent Graft will be presented for the first time at the Society of Interventional Radiology (SIR) Annual Scientific Meeting on April 12, 2026. Cirrhosis remains a significant global health challenge, with an estimated 58 million people worldwide living with the disease, according to the latest findings from the Global Burden of Disease study.[1] Cirrhosis can lead to portal hypertension, a serious condition that can result in life-threatening complications such as variceal bleeding and fluid build-up in the abdomen or chest. [2] Transjugular intrahepatic portosystemic shunt (TIPS) procedures help reduce symptoms caused by elevated portal pressure by lowering that pressure and improving blood flow. The Liverty(TM) TIPS Stent Graft is engineered to support individualized patient management, offering a 6-10 mm adjustable inner diameter and the broadest range of covered TIPS stent lengths currently available. Key features include a flexible, self-expanding nitinol frame and dual-layer ePTFE encapsulation with carbon impregnation on the inner surface, delivered fully constrained on a triaxial delivery system designed for placement accuracy, control and ease of use. "For patients living with complications of portal hypertension, access to safe, effective and adaptable treatment options is critical," said Rima Alameddine, worldwide president of Peripheral Intervention at BD. "With CE Marking of the Liverty(TM) TIPS Stent Graft, we're introducing an innovative, adjustable solution that helps physicians personalize therapy and improve the potential for long-term outcomes." BD also announced that data from the ARCH clinical study, a global, prospective, multi-center, single-arm clinical study assessing the safety and effectiveness of the Liverty(TM) TIPS Stent Graft for the treatment of complications from portal hypertension, will be presented for the first time on podium by Global Principal Investigator Prof. Ziv Haskal, MD, at SIR in April. "The Liverty(TM) TIPS Stent Graft represents an important advancement in how we care for patients with the serious complications of portal hypertension," said Dr. Haskal. "Its adjustable diameter and delivery design allow physicians to better match the shunt to a patient's unique physiology, a key consideration in safe and effective TIPS creation. The trial provides the first and only prospective data describing the results of small diameter calibrated TIPS for treating all the major complications of portal hypertension. I look forward to presenting the ARCH study results at SIR." In the United States, the Liverty(TM) TIPS Stent Graft it is an investigational device limited by U.S. law to investigational use only. About BD BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health(TM) by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson. ________________________________ [1] Duo H, You J, Du S, Yu M, Wu S, Yue P, et al. Liver cirrhosis in 2021: Global Burden of Disease study. PLOS One. 2025;20(7):e0328493. doi: 10.1371/journal.pone.032849 [2] Carroll A, Boike JR. Tips for TIPS recipients: A patient-focused guidance on TIPS. Clin Liver Dis (Hoboken). 2024;23(1):e0091. doi:10.1097/CLD.0000000000000091 SOURCE BD (Becton, Dickinson and Company) Released April 8, 2026
When every beat matters, BD helps clinicians eliminate blind spots with continuous, noninvasive blood pressure insight. PR Newswire Today at 3:50am PDT New HemoSphere Stream(TM) Module expands access to continuous, noninvasive arterial waveform data across compatible bedside monitors and broader care settings, giving more clinicians real-time insight into more patients. FRANKLIN LAKES, N.J., April 7, 2026 /PRNewswire/ - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of the HemoSphere Stream(TM) Module, a new innovation which gives clinicians continuous, noninvasive visibility into patients' blood pressure. The module delivers real-time, beat-to-beat arterial waveform data from a noninvasive finger cuff directly to compatible multiparameter patient monitors, helping clinicians close gaps between intermittent readings. "We're delivering real-time visibility of hemodynamic changes to more patients and care settings by making continuous, noninvasive monitoring available on compatible multiparameter monitors." said Tim Patz, worldwide president of Advanced Patient Monitoring at BD. "Patients who may not require an invasive arterial line can now benefit from continuous blood pressure monitoring, rather than intermittent checks." The compact HemoSphere Stream(TM) Module mounts easily to an IV pole, taking no additional footprint in clinical environments. When used with the VitaWave(TM) Plus Finger Cuff, the HemoSphere Stream(TM) Module serves as the interface that delivers continuous, noninvasive arterial blood pressure waveform data to compatible multiparameter monitors. Together with the finger cuff and supporting accessories, it comprises the VitaWave(TM) Plus System, which is designed for accuracy using technology validated against arterial line measurements. "Monitoring blood pressure and perfusion during and after surgery is key to reducing major complications after surgery. Anesthesia providers have been waiting for the availability of a simple way to measure continuous blood pressure noninvasively. This is a landmark technology to improve global patient safety," said Michael Scott, MD, Chair APSF Clinical Deterioration Committee. Continuous blood pressure helps reveal hemodynamic changes that may occur between intermittent blood pressure checks, which are typically taken every 3-5 minutes in the operating room. By providing a real-time view into blood pressure trends on any compatible patient monitor, the VitaWave(TM) Plus System supports the Anesthesia Patient Safety Foundation's (APSF) recommendations for continuous noninvasive hemodynamic monitoring to detect and treat intraoperative hypotension sooner. Visit www.bd.com/HemoSphereStream for more information about BD's Advanced Patient Monitoring solutions including HemoSphere Stream(TM) Module and VitaWave(TM) Plus System. About BD BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health(TM) by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson. | Contacts: | / | | Media | Investors | | Matt Marcus VP, Public Relations [email protected] | Shawn Bevec SVP, Investor Relations [email protected] | CAUTION: Federal (United States) law restricts this device to sale by or on the order of a physician. See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions and adverse events. SOURCE BD (Becton, Dickinson and Company) This is a paid placement. For further inquiries, please contact PR Newswire directly.